Fatal intratumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab: A case report

Table 1 Literature review on intratumoral hemorrhage related to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

Ref.	Year	Country	Sex	Age	Etiology of liver disease	Onset	Treatment	Prognosis
Mitsuyama et al[12]	2023	Japan	Male	73	NA	1 mo after atezolizumab/bevacizumab	Embolization	Survive
Matsumoto et al[13]	2023	Japan	Male	70	HBV	After 4th administration of atezolizumab/bevacizumab	Supportive care	Expire
The case reported in this study	2023	South Korea	Male	63	HCV	After 5th administration of atezolizumab/bevacizumab	Embolization	Expire

HBV: Hepatitis B virus; HCV: Hepatitis C virus.